Vaccines administered simultaneously: directions for new combination vaccines based on an historical review of the literature

Fletcher, Mark A.; Fabre, Pascal; Debois, Henri; Saliou, P.

doi:10.1016/j.ijid.2004.03.006

Cited by 12 publications

(7 citation statements)

References 79 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“… Compatibilidad: se puede aplicar el mismo día que la vacuna de bacilo de Calmette-Guerin (BCG), difteria, gripe, triple vírica, antitiroidea (oral e inyectable), hepatitis A y B, poliovirus, meningitis tetravalente de polisacáridos, téta-nos y tos ferina 44,45 . No existen datos que demuestren que exista interacción con la vacuna del virus del papiloma humano, encefalitis japonesa o varicela 44 .…”

Section: E19unclassified

“…No existen datos que demuestren que exista interacción con la vacuna del virus del papiloma humano, encefalitis japonesa o varicela 44 . No se debe aplicar, en el momento actual, a la vez que la de la meningitis tetravalente conjugada (Menveo®) 46,47 .…”

Section: E19unclassified

“… Vacuna contra la varicela y vacuna de la fiebre amarilla: no existen datos que demuestren interacción entre las dos vacunas 44 .…”

Section: E19unclassified

See 2 more Smart Citations

Ellos también viajan

García

2013

Rev Pediatr Aten Primaria

View full text Add to dashboard Cite

Child Travellers CountThe World Tourism Organization estimates that in 2013 tourism will continue growing and that in 2020 there will be 1.6 billion international trips taken. In 2011, there were 13.3 million trips taken abroad in Spain. There are very few figures for the number of international trips taken by Spanish children, but it is known that they form about 10% of travellers, a similar percentage to that found in US studies. Furthermore, during the last decade the immigrant population of Spain has grown, increasing the number of families returning to their home country to visit friends and relations. Although children make up a significant proportion of international travellers there is little information on pre-travel medicine for this group. The aim of this article is to describe the particularities of general advice, vaccination recommendations and malaria prevention for child international travellers, with the purpose of both infectious and non-infectious disease prevention.La Organización Mundial del Turismo estima que en el año 2013 el turismo continuará creciendo y que en el año 2020 los viajes internacionales van a ser 1,6 billones. En 2011 se realizaron en España 13,3 millones de viajes al extranjero. Las estimaciones de niños españoles que realizan un viaje internacional son muy escasas, pero se sabe que estos representan aproximadamente un 10% de los viajeros, porcentaje parecido al mencionado en estudios realizados en EE. UU. Además, en la última década en España ha aumentado la población inmigrante, lo que incrementa el número de familias que retornan a sus países de origen para visitar a sus amigos y familiares. Aunque los niños representan una parte importante de los viajeros internacionales, existe poca información acerca de la medicina previaje en este grupo de población. El objetivo de este artículo es describir las particularidades, en el niño que realiza un viaje internacional, de los consejos generales y las recomendaciones de vacunación y prevención de la malaria; se pretende prevenir no solo las enfermedades infecciosas, sino también las no infecciosas. Key words: . Además, en la última década en España se ha incrementado la población inmigrante, lo que aumenta el número de familias que retornan a sus países de origen para visitar a

show abstract

Section: E19unclassified

See 1 more Smart Citation

Ellos también viajan

García

2013

Rev Pediatr Aten Primaria

View full text Add to dashboard Cite

show abstract

“…The co-administration of vaccines (i.e., when two or more vaccines are administered during the same visit) or the use of combination/multivalent vaccines (i.e., vaccines containing two or more antigens in the same preparation) may enhance access to immunization in several ways. Indeed, these strategies have several potential benefits, including improved patient convenience and compliance, simplified immunization schedules, fewer missed opportunities to vaccinate, reduced costs, and logistical advantages [ 15 , 16 , 17 , 18 ].…”

Section: Introductionmentioning

confidence: 99%

COVID-19 and Seasonal Influenza Vaccination: Cross-Protection, Co-Administration, Combination Vaccines, and Hesitancy

et al. 2022

View full text Add to dashboard Cite

SARS-CoV-2 and influenza are the main respiratory viruses for which effective vaccines are currently available. Strategies in which COVID-19 and influenza vaccines are administered simultaneously or combined into a single preparation are advantageous and may increase vaccination uptake. Here, we comprehensively review the available evidence on COVID-19/influenza vaccine co-administration and combination vaccine candidates from the standpoints of safety, immunogenicity, efficacy, policy and public acceptance. While several observational studies have shown that the trained immunity induced by influenza vaccines can protect against some COVID-19-related endpoints, it is not yet understood whether co-administration or combination vaccines can exert additive effects on relevant outcomes. In randomized controlled trials, co-administration has proved safe, with a reactogenicity profile similar to that of either vaccine administered alone. From the immunogenicity standpoint, the immune response towards four influenza strains and the SARS-CoV-2 spike protein in co-administration groups is generally non-inferior to that seen in groups receiving either vaccine alone. Several public health authorities have advocated co-administration. Different combination vaccine candidates are in (pre)-clinical development. The hesitancy towards vaccine co-administration or combination vaccines is a multifaceted phenomenon and may be higher than the acceptance of either vaccine administered separately. Public health implications are discussed.

show abstract

“…Rigorous clinical trials have assessed the safety and immunogenicity of most currently approved vaccines. However, data are limited with respect to interactions of many vaccines, including the YFV vaccine, with other vaccines including all currently available flavivirus vaccines [23][24][25][26][27][28][29][30][31][32].…”

Section: Introductionmentioning

confidence: 99%

Safety and immunogenicity following co-administration of Yellow fever vaccine with Tick-borne encephalitis or Japanese encephalitis vaccines: Results from an open label, non-randomized clinical trial

Sandberg

Löfling

Varnaitė

et al. 2022

Preprint

View full text Add to dashboard Cite

Background Flavivirus infections pose a significant global health burden underscoring the need for the development of safe and efficient vaccination strategies. Available flavivirus vaccines are from time to time concomitantly delivered to individuals in need. Co-administration of different vaccines saves time and visits to health care units and vaccine clinics. It serves to provide protection against multiple pathogens in a shorter time-span, both for individuals living in, or travelling to, endemic areas. However, safety and immunogenicity-related responses have not been appropriately evaluated upon concomitant delivery of these vaccines. Therefore, we performed an open label, non-randomized clinical trial studying the safety and immunogenicity following concomitant delivery of the Yellow fever virus (YFV) vaccine with Tick-borne encephalitis virus (TBEV) and Japanese encephalitis virus (JE) virus vaccines. Methods and findings Following screening, healthy study subjects were enrolled into different cohorts receiving either TBEV and YFV vaccines, JEV and YFV vaccines, or in control groups receiving only the TBEV, JEV, or YFV vaccine. Concomitant delivery was given in the same or different upper arms for comparison in the co-vaccination cohorts. Adverse effects were recorded throughout the study period and blood samples were taken before and at multiple time-points following vaccination to evaluate immunological responses to the vaccines. Adverse events were predominantly mild in the study groups. Four serious adverse events (SAE) were reported throughout the trial, none of them deemed related to vaccination. The development of neutralizing antibodies (nAbs) against TBEV, JEV, or YFV was not affected by the concomitant vaccination strategy. Concomitant vaccination in the same or different upper arms did not significantly affect safety or immunogenicity-related outcomes. Exploratory studies on immunological effects were additionally performed and included studies of lymphocyte activation, correlates associated with germinal center activation, and plasmablast expansion. Conclusions Inactivated TBEV or JEV vaccines can be co-administered with the live attenuated YFV vaccine without an increased risk of adverse events and without reduced development of nAbs to the respective viruses. The vaccines can be delivered in the same upper arm without negative outcome.

show abstract

Vaccines administered simultaneously: directions for new combination vaccines based on an historical review of the literature

Cited by 12 publications

References 79 publications

Ellos también viajan

Ellos también viajan

COVID-19 and Seasonal Influenza Vaccination: Cross-Protection, Co-Administration, Combination Vaccines, and Hesitancy

Safety and immunogenicity following co-administration of Yellow fever vaccine with Tick-borne encephalitis or Japanese encephalitis vaccines: Results from an open label, non-randomized clinical trial

Contact Info

Product

Resources

About